Camrelizumab
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Extranodal Lymphoma
Conditions
Primary Extranodal Lymphoma, DLBCL
Trial Timeline
Jun 1, 2022 → Dec 1, 2024
NCT ID
NCT05093140About Camrelizumab
Camrelizumab is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Primary Extranodal Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05093140. Target conditions include Primary Extranodal Lymphoma, DLBCL.
What happened to similar drugs?
20 of 20 similar drugs in Primary Extranodal Lymphoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05547737 | Pre-clinical | UNKNOWN |
| NCT05093140 | Phase 2 | UNKNOWN |
| NCT05043688 | Phase 3 | Recruiting |
| NCT04805736 | Phase 2 | Completed |
| NCT05099848 | Phase 2 | UNKNOWN |
| NCT03912857 | Phase 2 | UNKNOWN |
| NCT02742935 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Extranodal Lymphoma